Jeffrey Cranmer

RT @steveusdin1: The leaked Trump administration 2026 HHS budget is sickening. If enacted, it will destroy American science. NIH budget sla…

RT @KevinH_PhD: After 21 years at my dream job, I’m very sad to announce my early retirement from the National Institutes of Health. My lif…

RT @PHLEaglesNation: Go Birds, @EmmittSmith22.

Makary filling key @US_FDA spots with Capitol Hill alum Grace Graham, Washington lawyer Lowell Zeta, @BioCentury's @steveusdin1 has learned. They'll join the agency's Office of the Commissioner

Shanghai ADC play Duality braved one of HK's worst downturns of past 20 yrs to stick its landing on the HKSE, offering hope to China biotechs that have been suffering through a multiyear financing drought. I took a closer look in today's @BioCentury : https://t.co/QjXnFDw2Xv

Small molecule #Alzheimer's tx hits Ph 3 setback at #ADPD2025, but study's PIs argue for a subgroup effect in early-stage patients and a new surrogate endpoint -- hippocampal volume. My @BioCentury colleague @SelinaMKoch reports on the data as presented in Vienna at @adpdnet

"Not exactly a pick-me-up" says my @BioCentury pal @BioPharmaJosh about the new #BioCenturyThisWeek biotech podcast! But trust him, it's the stuff you need to know about what's happening to @US_FDA & $XBI. w/@steveusdin1 @FishburnSimone @StephenPHansen https://t.co/kApqNAoe54

RT @ScottGottliebMD: 🧵 Twenty-five years ago, it was common to hear complaints about a “drug lag”—the perception that Europeans routinely e…

RT @LifeSciVC: FDA turmoil is creating huge uncertainty for biotech... so much institutional knowledge is being lost... and upheaval is nev…

Just after biotech started to see some green shoots, we're back in a bear market. $XBI cratering in the wake of Peter Marks departure from @US_FDA, looming tariff threat. #FAFO

There's a short window left to halt the brain drain @US_FDA, says @BioCentury's @steveusdin1. Senior managers, office directors, and reviewers with decades of experience have accepted or plan to accept buyout offers. Anxiety is through the roof. https://t.co/aXtwhwslZ2

Shares of WuXi AppTec and WuXi Biologics are closing in on pre-Biosecure Act levels now that the legislation that sought to rein in China CDMOs and genomics companies appears to have faded away. Read my latest in @BioCentury : https://t.co/GkJPU1KsYu